ArticleJournal of cardiothoracic surgery2026
MiR-19a-3p: a potential biomarker for predicting cardiac risk in anderson-fabry disease.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs(miRNAs) have been shown to suppress the onset and progression of heart disease and have recently been widely proposed as biomarkers. However, few literatures have been reported on whether they protect against Anderson-Fabry-induced myocardial damage.
objectiveThe aim was to explore whether miR-19a-3p could be used as a biomarker for the diagnosis and risk assessment of Anderson-Fabry disease (AFD), distinguishing AFD from healthy controls and myocardial damage caused by AFD.
methods60 AFD patients and an equal number of healthy controls were recruited to analyze miR-19a-3p expression. ROC analysis evaluated their diagnostic ability, and statistical analysis demonstrated the association of clinical indicators of cardiac damage with miR-19a-3p.
results53.3% of AFD patients exhibited cardiac damage, with notable structural changes in cardiac characteristics. MiR-19a-3p expression level was downregulated in AFD and AFD cardiomyopathy patients and showed high diagnostic accuracy for identifying both AFD and associated cardiac injury. It negatively correlated with severity of cardiac injury. Multivariate analysis identified miR-19a-3p as a significant independent protective factor in cardiac damage in AFD.
conclusionThe study identified downregulated miR-19a-3p as a potent diagnostic biomarker for AFD and its associated cardiomyopathy. MiR-19a-3p was established as an independent protective factor in cardiac damage. Thus, it was proposed as a promising candidate biomarker for AFD cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.